Neratinib was recently approved by the FDA for extended adjuvant treatment of HER2+ breast cancer. The ExteNET trial showed improvement in invasive disease-free survival (iDFS) in the neratinib armcompared with placebo. The benefit was more pronounced in patients with estrogen receptor-positive (ER+)/ HER2+ tumors, suggesting bidirectional cross-talk between the ER and HER pathways.
|Original language||English (US)|
|Number of pages||3|
|Journal||Clinical Cancer Research|
|State||Published - Aug 1 2018|
ASJC Scopus subject areas
- Cancer Research